TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: triglyceride (TG) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HBV-DNA <400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT 1x ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-year survival
Endpoint domain: Mortality/survival
Primary endpoint: lower mortality associated with folic acid therapy
Endpoint domain: Mortality/survival
Primary endpoint: Intraocular pressure elevations of 5 mm Hg or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer patient-initiated calls
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: functional limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: adjustment to family life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: sleep loss
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: High MRI activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cumulative probabilities of CDMS
Endpoint domain: Mortality/survival
Primary endpoint: Systemic inflammation markers (hsCRP, IL‐6, IL‐8, TNF‐α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apnoea times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emergence times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infant serum concentration of nevirapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in primary subjective symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in rose bengal staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fewer signs of outward distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths from any cause
Endpoint domain: Mortality/survival
Primary endpoint: 12-month prevalence of eczema
Endpoint domain: Adverse events/effects
Primary endpoint: lifetime prevalence of atopic sensitization
Endpoint domain: Adverse events/effects
Primary endpoint: lifetime prevalence of wheeze
Endpoint domain: Adverse events/effects
Primary endpoint: Mean posttreatment NLF severity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection site erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of oppositional and conduct behavior symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social behavior outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alpha-MTrp uptake in the hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of WP smoking among medical students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p16 positivity as a prognostic factor
Endpoint domain: Mortality/survival
Primary endpoint: EGFR expression as a prognostic marker
Endpoint domain: Mortality/survival
Primary endpoint: coagulase‐negative staphylococci sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Basal glucose production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin-mediated glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in mood on the Profile of Mood States depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Employment earnings after diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Economic circumstances
Primary endpoint: cardioprotective effects of volatile agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived health threat of childhood obesity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of invasive cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Screening uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Breast cancer mortality impact
Endpoint domain: Mortality/survival
Primary endpoint: mean blood volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean minimum levels of Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean minimum levels of HcT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acquisition of surgical skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative morphine usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAZ increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of recurrent diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of FC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IIEF-EF domain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SEP2 and SEP3 success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of posttreatment leiomyoma enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of significant residual intratumoral perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change in OSDI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MASS difference between groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variability in exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AAA expansion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum interleukin‐6 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphopenia at 4 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in glomerulopathy index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean value of rheobase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6MWT distance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea reduction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive function score (Mini-Mental State Examination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global severity of dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anesthetic quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified ADAS‐Cog scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Global Assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration-time curve (AUC(0-infinity)) of tizanidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bronchodilator use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: growth velocity suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ureteral stone expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Target BP achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of adverse health events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in constipation-associated quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Parafoveal area thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leakage area on fluorescein angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Number of injurious falls
Endpoint domain: Adverse events/effects
Primary endpoint: TWSNOT‐22 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perform activities of daily living (ADL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced opiate consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced analgesic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced production of IL-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in gastric mucosal prostaglandin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of gastric ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in serum thromboxane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Q-TWiST score
Endpoint domain: Mortality/survival
Primary endpoint: Optimal risk factor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the Mediterranean diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality assessed by the Short Physical Performance Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with dry dressings on day 1 postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with increased leakage of wounds on days 2 and 3 postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of dressing changes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: food cravings and appetite scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Underreporting rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight status (overweight and obese)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age group (51 years or older)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of IL-1ra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: one-leg standing (left support) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-leg standing (right support) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h Upro (proteinuria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: therapeutic dose of ciclosporin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: adverse effects associated with MTW
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with good outcomes at three months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rates of peripartal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to hyperinsufflation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anal leakage of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Psychosocial function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: systolic BP at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diastolic BP at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: requirement for antihypertensive medication during follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Uterine quiescence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal complications
Endpoint domain: Adverse events/effects
Primary endpoint: first-time female-condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived personality traits and emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of metachronous lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Shoulder pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema severity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute renal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pao2/Fio2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fatal and non-fatal deep vein thrombosis or pulmonary embolism
Endpoint domain: Adverse events/effects
Primary endpoint: Major haemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in ambulatory BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Highest Plasma Drug Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete success rate for AGV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal graft clarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma norepinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urine norepinephrine/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart rate variability (LF-HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Explosive leg power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive leg power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of aborted myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: STR before PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tumor tissue proliferation indexes (Ki-67 and PCNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sputum conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse drug events
Endpoint domain: Adverse events/effects
Primary endpoint: National Institute of Health Stroke Scale (NIHSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activity of daily living (ADL) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum TG, TC, and LDL‐C content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LogMAR VA change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VF-14 score change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: QALYs change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: benefit from ICBT
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: decreased risk of reporting alcohol-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative PGE2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycerol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma basal concentrations of glicentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative neutrophil CD11b/CD18 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvements in total IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reperfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance on memory tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective alertness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of grade 3 motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocellular insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference of intracoronary CT numbers between second and first CCTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IBS-related outcome scales improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cost-effectiveness of ICBT
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Mean birth weight difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge/skill to identify and engage in collaborative decision making
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Field of anhidrotic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement based on the Wrinkle Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with nosocomial infection
Endpoint domain: Adverse events/effects
Primary endpoint: post-examination discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bone loss percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum E2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: lifetime prevalence of migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lifetime prevalence of cluster headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complication rate for any severity complication
Endpoint domain: Adverse events/effects
Primary endpoint: rate for moderate complications
Endpoint domain: Adverse events/effects
Primary endpoint: Fall risk measure of functional ambulation profile (FAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnea improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood pressure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hospitalized days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: postoperative recovery satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mortality due to chronic liver dysfunction
Endpoint domain: Mortality/survival
Primary endpoint: uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of ligation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isthmocele formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMT (Residual Myometrial Thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower extremity muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue oxygen saturation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI z-score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in dietary intake of vegetables, fruits, and fruit juice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global impression
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: improvement in math performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: improvement in behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing